We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Several Genes Linked to Long QT Syndrome Reappraised

By LabMedica International staff writers
Posted on 20 Feb 2020
Long QT syndrome (LQTS) is the first described and most common inherited arrhythmia. More...
Over the last 25 years, multiple genes have been reported to cause this condition and are routinely tested in patients.

It is now known that that some variants that were thought to be rare are in fact common in populations, and that rare genetic variants are collectively extremely common, with the majority of rare variants not causative for Mendelian disease. Because of dramatic changes in our understanding of human genetic variation, reappraisal of reported genetic causes for LQTS is required.

A large team of scientists led by those at the Toronto General Hospital Research Institute (Toronto, ON, Canada) divided into three gene curation teams who independently assessed each of the 17 genes associated with long QT syndrome to classify the evidence linking them to the disease as either definitive, strong, moderate, or limited. A panel convened by the Clinical Genome Resource (ClinGen) has now re-examined the evidence linking these genes to long QT syndrome.

The investigators found that only three of the 17 genes have strong evidence for their connection to the common form of the condition and four genes had evidence linking them to atypical long QT syndrome. According to the authors, many of the other genes should not be considered when pursuing genetic testing for long QT syndrome because of their tenuous link to the disease.

The three genes, KCNQ1, KCNH2 and SCN5A, were classified as having definitive evidence linking them to typical long QT syndrome, as their association was supported by linkage analyses in multiple families, as well as genetic and experimental evidence. Four other genes, CALM1, CALM2, CALM3, and TRDN, had definitive or strong evidence linking them to atypical forms of long QT syndrome, such as ones that present in early childhood, often alongside other symptoms such as seizures and developmental delay.

The evidence linking six genes to long QT syndrome was classified as disputed. For four of these genes, the publications linking them to the condition described candidate gene approaches that the curation teams gave less weight, while the evidence linking the other two genes came from linkage analyses in large families that the scientists said had significant limitations.

Michael Gollob, MD, FRCP. an Associate Professor of Cardiology and senior author of the study, said, “Our study highlights the need to take a step back and to critically evaluate the level of evidence for all reported gene-disease associations, especially when applying genetic testing for diagnostic purposes in our patients. Testing genes with insufficient evidence to support disease causation only creates a risk of inappropriately interpreting the genetic information and leading to patient harm.” The study was published on January 27, 2020 in the journal Circulation.

Related Links:
Toronto General Hospital Research Institute


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.